Proshares Trust (ZBIO) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.
- Zenas BioPharma's Income from Continuing Operations fell 3339.64% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 5006.66%. This contributed to the annual value of -$161.3 million for FY2024, which is 33461.64% down from last year.
- Zenas BioPharma's Income from Continuing Operations amounted to -$51.5 million in Q3 2025, which was down 3339.64% from -$52.2 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's Income from Continuing Operations ranged from a high of $35.6 million in Q3 2023 and a low of -$56.5 million during Q4 2024
- For the 3-year period, Zenas BioPharma's Income from Continuing Operations averaged around -$31.9 million, with its median value being -$38.0 million (2024).
- In the last 5 years, Zenas BioPharma's Income from Continuing Operations tumbled by 20837.08% in 2024 and then plummeted by 2076.62% in 2025.
- Zenas BioPharma's Income from Continuing Operations (Quarter) stood at -$24.8 million in 2023, then plummeted by 128.15% to -$56.5 million in 2024, then rose by 8.91% to -$51.5 million in 2025.
- Its Income from Continuing Operations stands at -$51.5 million for Q3 2025, versus -$52.2 million for Q2 2025 and -$33.6 million for Q1 2025.